Expired activity
Please go to the PowerPak homepage and select a course.

New Guidelines and Strategies to Manage CVD Residual Risk: Beyond Statin Therapy

Jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and Medtelligence.

This activity is supported by an independent educational grant from Amarin Pharma Inc.

Release date:

September 19, 2019

Expiration date:

September 19, 2020

Estimated time to complete the activity:

1.0 hours

Program Overview

This innovative CPE activity features a leading international expert addressing the reduction of residual risk in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD) beyond LDL-C lowering. The program is based on a live satellite symposium and will include the following topics:

  • Pharmacist implications of new cholesterol guidelines
  • Recent cardiovascular outcomes trials outcomes trials such as IMPROVE-IT, FOURIER, ODYSSEY OUTCOMES, and REDUCE-IT that have had major clinical implications for managing ASCVD risk

Target Audience

This activity is intended for pharmacists and other healthcare professionals engaged in the management of patients with or at high risk of atherosclerotic cardiovascular disease.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Apply evidence-based guidelines and recent randomized clinical trial evidence to lifestyle and therapeutic approaches for managing patients at high risk of cardiovascular events
  • Describe the spectrum of major recent ASCVD randomized cardiovascular outcomes trials


Michael B. Bottorff, PharmD, Chair
Professor and Chair
Department of Pharmacy Practice
Manchester College of Pharmacy
Fort Wayne, IN

Joint Accreditation Statement

jointly accredited by (ACCME)In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this enduring activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-19-920-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


  • Michael Bottorff, PharmD: Consulting Fees: Esperion; Fees for Non-CME/CE Services: Pfizer

Planners and Managers

The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CPE credit for this activity. During the period September 19, 2019 through September 19, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, complete the post-test and evaluation. Participants who successfully complete the activity, post-test, and evaluation will have a statement of credit made available immediately.

If you have any questions regarding the CME certification of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.



Required Computer Hardware/Software

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Additional information

For more information, contact Medtelligence at info@medtelligence.net.